Log in
NASDAQ:RWLK

ReWalk Robotics Competitors

$1.29
-0.01 (-0.77 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.20
Now: $1.29
$1.34
50-Day Range
$1.03
MA: $1.16
$1.52
52-Week Range
$0.41
Now: $1.29
$3.04
Volume723,598 shs
Average Volume1.22 million shs
Market Capitalization$24.72 million
P/E RatioN/A
Dividend YieldN/A
Beta3.42

Competitors

ReWalk Robotics (NASDAQ:RWLK) Vs. ISRG, EW, ALGN, ZBH, SNN, and STE

Should you be buying RWLK stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to ReWalk Robotics, including Intuitive Surgical (ISRG), Edwards Lifesciences (EW), Align Technology (ALGN), Zimmer Biomet (ZBH), Smith & Nephew (SNN), and Steris (STE).

Intuitive Surgical (NASDAQ:ISRG) and ReWalk Robotics (NASDAQ:RWLK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Profitability

This table compares Intuitive Surgical and ReWalk Robotics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
ReWalk Robotics-282.04%-109.54%-54.24%

Institutional & Insider Ownership

86.9% of Intuitive Surgical shares are held by institutional investors. Comparatively, 3.8% of ReWalk Robotics shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 6.9% of ReWalk Robotics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Intuitive Surgical and ReWalk Robotics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion19.31$1.38 billion$9.9573.92
ReWalk Robotics$4.87 million5.08$-15,550,000.00($2.70)-0.48

Intuitive Surgical has higher revenue and earnings than ReWalk Robotics. ReWalk Robotics is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Intuitive Surgical and ReWalk Robotics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical381202.39
ReWalk Robotics00103.00

Intuitive Surgical currently has a consensus target price of $720.4737, suggesting a potential downside of 2.04%. ReWalk Robotics has a consensus target price of $2.50, suggesting a potential upside of 93.80%. Given ReWalk Robotics' stronger consensus rating and higher possible upside, analysts clearly believe ReWalk Robotics is more favorable than Intuitive Surgical.

Risk & Volatility

Intuitive Surgical has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, ReWalk Robotics has a beta of 3.42, indicating that its stock price is 242% more volatile than the S&P 500.

Summary

Intuitive Surgical beats ReWalk Robotics on 10 of the 14 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and ReWalk Robotics (NASDAQ:RWLK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares Edwards Lifesciences and ReWalk Robotics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences17.21%29.11%18.32%
ReWalk Robotics-282.04%-109.54%-54.24%

Institutional and Insider Ownership

79.7% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 3.8% of ReWalk Robotics shares are owned by institutional investors. 1.5% of Edwards Lifesciences shares are owned by company insiders. Comparatively, 6.9% of ReWalk Robotics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Edwards Lifesciences and ReWalk Robotics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion11.50$1.05 billion$1.8643.23
ReWalk Robotics$4.87 million5.08$-15,550,000.00($2.70)-0.48

Edwards Lifesciences has higher revenue and earnings than ReWalk Robotics. ReWalk Robotics is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Edwards Lifesciences and ReWalk Robotics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences251302.55
ReWalk Robotics00103.00

Edwards Lifesciences presently has a consensus target price of $86.5926, suggesting a potential upside of 7.69%. ReWalk Robotics has a consensus target price of $2.50, suggesting a potential upside of 93.80%. Given ReWalk Robotics' stronger consensus rating and higher possible upside, analysts plainly believe ReWalk Robotics is more favorable than Edwards Lifesciences.

Risk & Volatility

Edwards Lifesciences has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, ReWalk Robotics has a beta of 3.42, indicating that its share price is 242% more volatile than the S&P 500.

Summary

Edwards Lifesciences beats ReWalk Robotics on 10 of the 14 factors compared between the two stocks.

Align Technology (NASDAQ:ALGN) and ReWalk Robotics (NASDAQ:RWLK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares Align Technology and ReWalk Robotics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Align Technology76.00%74.03%49.70%
ReWalk Robotics-282.04%-109.54%-54.24%

Institutional and Insider Ownership

86.4% of Align Technology shares are owned by institutional investors. Comparatively, 3.8% of ReWalk Robotics shares are owned by institutional investors. 1.2% of Align Technology shares are owned by company insiders. Comparatively, 6.9% of ReWalk Robotics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Align Technology and ReWalk Robotics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$2.41 billion15.37$442.78 million$4.9694.67
ReWalk Robotics$4.87 million5.08$-15,550,000.00($2.70)-0.48

Align Technology has higher revenue and earnings than ReWalk Robotics. ReWalk Robotics is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Align Technology and ReWalk Robotics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Align Technology24802.43
ReWalk Robotics00103.00

Align Technology presently has a consensus target price of $368.3077, suggesting a potential downside of 21.56%. ReWalk Robotics has a consensus target price of $2.50, suggesting a potential upside of 93.80%. Given ReWalk Robotics' stronger consensus rating and higher possible upside, analysts plainly believe ReWalk Robotics is more favorable than Align Technology.

Risk & Volatility

Align Technology has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, ReWalk Robotics has a beta of 3.42, indicating that its share price is 242% more volatile than the S&P 500.

Summary

Align Technology beats ReWalk Robotics on 10 of the 14 factors compared between the two stocks.

Zimmer Biomet (NYSE:ZBH) and ReWalk Robotics (NASDAQ:RWLK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Analyst Ratings

This is a summary of current ratings for Zimmer Biomet and ReWalk Robotics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zimmer Biomet141722.83
ReWalk Robotics00103.00

Zimmer Biomet presently has a consensus target price of $151.9565, suggesting a potential upside of 6.48%. ReWalk Robotics has a consensus target price of $2.50, suggesting a potential upside of 93.80%. Given ReWalk Robotics' stronger consensus rating and higher possible upside, analysts plainly believe ReWalk Robotics is more favorable than Zimmer Biomet.

Profitability

This table compares Zimmer Biomet and ReWalk Robotics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zimmer Biomet0.52%10.07%4.93%
ReWalk Robotics-282.04%-109.54%-54.24%

Valuation and Earnings

This table compares Zimmer Biomet and ReWalk Robotics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zimmer Biomet$7.98 billion3.70$1.13 billion$7.8718.13
ReWalk Robotics$4.87 million5.08$-15,550,000.00($2.70)-0.48

Zimmer Biomet has higher revenue and earnings than ReWalk Robotics. ReWalk Robotics is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

87.2% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 3.8% of ReWalk Robotics shares are owned by institutional investors. 0.4% of Zimmer Biomet shares are owned by company insiders. Comparatively, 6.9% of ReWalk Robotics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Zimmer Biomet has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, ReWalk Robotics has a beta of 3.42, indicating that its share price is 242% more volatile than the S&P 500.

Summary

Zimmer Biomet beats ReWalk Robotics on 10 of the 15 factors compared between the two stocks.

ReWalk Robotics (NASDAQ:RWLK) and Smith & Nephew (NYSE:SNN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ReWalk Robotics and Smith & Nephew, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ReWalk Robotics00103.00
Smith & Nephew23502.30

ReWalk Robotics presently has a consensus price target of $2.50, suggesting a potential upside of 93.80%. Smith & Nephew has a consensus price target of $42.00, suggesting a potential upside of 9.15%. Given ReWalk Robotics' stronger consensus rating and higher possible upside, analysts clearly believe ReWalk Robotics is more favorable than Smith & Nephew.

Profitability

This table compares ReWalk Robotics and Smith & Nephew's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ReWalk Robotics-282.04%-109.54%-54.24%
Smith & NephewN/AN/AN/A

Valuation & Earnings

This table compares ReWalk Robotics and Smith & Nephew's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ReWalk Robotics$4.87 million5.08$-15,550,000.00($2.70)-0.48
Smith & Nephew$5.14 billion3.28$600 million$2.0418.86

Smith & Nephew has higher revenue and earnings than ReWalk Robotics. ReWalk Robotics is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

3.8% of ReWalk Robotics shares are owned by institutional investors. Comparatively, 9.1% of Smith & Nephew shares are owned by institutional investors. 6.9% of ReWalk Robotics shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

ReWalk Robotics has a beta of 3.42, indicating that its stock price is 242% more volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

Summary

Smith & Nephew beats ReWalk Robotics on 9 of the 14 factors compared between the two stocks.

ReWalk Robotics (NASDAQ:RWLK) and Steris (NYSE:STE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Profitability

This table compares ReWalk Robotics and Steris' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ReWalk Robotics-282.04%-109.54%-54.24%
Steris13.69%16.24%9.19%

Volatility & Risk

ReWalk Robotics has a beta of 3.42, indicating that its stock price is 242% more volatile than the S&P 500. Comparatively, Steris has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ReWalk Robotics and Steris, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ReWalk Robotics00103.00
Steris01302.75

ReWalk Robotics presently has a consensus price target of $2.50, suggesting a potential upside of 93.80%. Steris has a consensus price target of $200.00, suggesting a potential upside of 6.64%. Given ReWalk Robotics' stronger consensus rating and higher possible upside, analysts clearly believe ReWalk Robotics is more favorable than Steris.

Institutional & Insider Ownership

3.8% of ReWalk Robotics shares are owned by institutional investors. Comparatively, 90.0% of Steris shares are owned by institutional investors. 6.9% of ReWalk Robotics shares are owned by company insiders. Comparatively, 1.2% of Steris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares ReWalk Robotics and Steris' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ReWalk Robotics$4.87 million5.08$-15,550,000.00($2.70)-0.48
Steris$3.03 billion5.26$407.61 million$5.6433.25

Steris has higher revenue and earnings than ReWalk Robotics. ReWalk Robotics is trading at a lower price-to-earnings ratio than Steris, indicating that it is currently the more affordable of the two stocks.

Summary

Steris beats ReWalk Robotics on 10 of the 14 factors compared between the two stocks.


ReWalk Robotics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.5$735.48-0.3%$86.46 billion$4.48 billion83.77Insider Selling
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.4$80.41-1.3%$49.99 billion$4.35 billion69.12Earnings Announcement
Analyst Report
Unusual Options Activity
Analyst Revision
Heavy News Reporting
Align Technology logo
ALGN
Align Technology
1.7$469.56-3.5%$37.00 billion$2.41 billion21.36Earnings Announcement
Analyst Upgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
Heavy News Reporting
Zimmer Biomet logo
ZBH
Zimmer Biomet
2.0$142.71-0.2%$29.55 billion$7.98 billion891.99Analyst Report
Smith & Nephew logo
SNN
Smith & Nephew
1.8$38.48-0.0%$16.85 billion$5.14 billion18.86
Steris logo
STE
Steris
1.7$187.54-0.3%$15.95 billion$3.03 billion38.99
MSA Safety logo
MSA
MSA Safety
1.4$143.49-0.2%$5.58 billion$1.40 billion36.79Upcoming Earnings
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$30.66-0.1%$3.98 billion$920.90 million-28.92Heavy News Reporting
Avanos Medical logo
AVNS
Avanos Medical
1.2$38.07-0.7%$1.82 billion$697.60 million-108.77Heavy News Reporting
Inogen logo
INGN
Inogen
1.3$28.01-1.5%$618.07 million$361.94 million93.37Heavy News Reporting
Establishment Labs logo
ESTA
Establishment Labs
1.1$24.63-0.9%$575.53 million$89.57 million-11.56
Invacare logo
IVC
Invacare
1.4$7.16-6.0%$246.44 million$927.96 million-5.68Upcoming Earnings
Sientra logo
SIEN
Sientra
1.5$4.62-0.9%$232.43 million$83.70 million-2.19
Lakeland Industries logo
LAKE
Lakeland Industries
1.5$24.54-3.5%$195.83 million$107.81 million9.74
ConforMIS logo
CFMS
ConforMIS
1.3$0.74-2.0%$57.47 million$77.43 million-1.95
CLGN
CollPlant Biotechnologies
1.1$6.98-2.4%$39.58 million$2.32 million-2.53
Histogenics logo
HSGX
Histogenics
0.8$0.32-0.0%$30.59 millionN/A-0.41
AHPI
Allied Healthcare Products
0.5$4.94-1.0%$19.81 million$31.89 million-6.77
POAI
Predictive Oncology
1.2$0.86-2.3%$13.26 million$1.41 million-0.12
NAOV
NanoVibronix
1.1$0.69-1.4%$7.30 million$530,000.00-1.11High Trading Volume
This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.